Despite good initial clinical responses to ADT (indicated by tumour regression and/or reduced serum PSA), most prostate cancers develop survival strategies that allow them to survive and proliferate in the presence of ADT (Scher and Heller, 2000). This evidence concerns the gene KLK3 and neoplasm.